Revvity, Inc. announced the launch of the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection product to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear.

Using capillary dried blood spots (DBS) for simple, scalable sample collection, the 3-plex assay is processed on Revvity’s GSP instrument. This end-to-end workflow, which includes reagents, instrumentation, and software, can detect at-risk individuals months or years before symptoms, enabling early intervention and disease-modifying treatment.

The GSP T1D 3plex kit is designed to meet the needs of emerging national T1D screening programs. The GSP T1D 3plex kit will initially be available in Europe and all markets that accept CE IVD-marked products. The GSP T1D 3plex is not a U.S. Food and Drug Administration (FDA)-cleared device.

Visit Revvity for more information